{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:24:07Z","timestamp":1770481447452,"version":"3.49.0"},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the effectiveness of the anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in the treatment of B-cell lymphoma, its efficacy remains variable and often modest. It seems likely that a combination of multiple mechanisms, such as complement-dependent cytotoxicity (CDC) and apoptotic signaling, underlies the therapeutic success of anti-CD20 mAbs. Unfortunately, all the current anti-CD20 mAbs effective in CDC are relatively inactive in signaling cell death and vice versa. In this study, we developed two genetically engineered tetravalent antibodies (TetraMcAb) respectively derived from the anti-CD20 mAbs C2B8 and 2F2. TetraMcAbs, with a molecular mass only 25 kDa higher than native divalent antibodies (DiMcAb), were shown not only to be as effective in mediating CDC and antibody-dependent cellular cytotoxicity against B-lymphoma cells as DiMcAbs but also to have antiproliferative and apoptosis-inducing activity markedly superior to that of DiMcAbs. Interestingly, whereas 2F2 and C2B8 were equally effective in inducing cell growth arrest and apoptosis, the functions of their tetravalent versions, 2F2(ScFvHL)4-Fc and C2B8(ScFvHL)4-Fc, were significantly different. 2F2(ScFvHL)4-Fc exhibited exceptionally more potent antiproliferative and apoptosis-inducing activity than that of C2B8(ScFvHL)4-Fc. Immunotherapeutic studies further showed that 2F2(ScFvHL)4-Fc was far more effective in prolonging the survival of severe combined immunodeficient mice bearing systemic Daudi or Raji tumors than C2B8, 2F2, and C2B8(ScFvHL)4-Fc, suggesting that it might be a promising therapeutic agent for B-cell lymphoma. [Cancer Res 2008;68(7):2400\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-6663","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T19:44:16Z","timestamp":1207079056000},"page":"2400-2408","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity"],"prefix":"10.1158","volume":"68","author":[{"given":"Bohua","family":"Li","sequence":"first","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"},{"name":"2Shanghai Center for Cell Engineering and Antibody, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Shi","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhu","family":"Qian","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"},{"name":"2Shanghai Center for Cell Engineering and Antibody, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dapeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Hou","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"},{"name":"2Shanghai Center for Cell Engineering and Antibody, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Dai","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"},{"name":"2Shanghai Center for Cell Engineering and Antibody, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajun","family":"Guo","sequence":"additional","affiliation":[{"name":"1International Joint Cancer Institute, Second Military Medical University and"},{"name":"2Shanghai Center for Cell Engineering and Antibody, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"2022061700302244800_B1","doi-asserted-by":"crossref","unstructured":"Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A\u20081988; 85: 208\u201312.","DOI":"10.1073\/pnas.85.1.208"},{"key":"2022061700302244800_B2","doi-asserted-by":"crossref","unstructured":"Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today\u20081994; 15: 450\u20134.","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"2022061700302244800_B3","doi-asserted-by":"crossref","unstructured":"Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol\u20082005; 23: 6421\u20138.","DOI":"10.1200\/JCO.2005.06.004"},{"key":"2022061700302244800_B4","doi-asserted-by":"crossref","unstructured":"Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today\u20082003; 8: 503\u201310.","DOI":"10.1016\/S1359-6446(03)02714-4"},{"key":"2022061700302244800_B5","doi-asserted-by":"crossref","unstructured":"Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol\u20081998; 10: 548\u201351.","DOI":"10.1097\/00001622-199811000-00012"},{"key":"2022061700302244800_B6","doi-asserted-by":"crossref","unstructured":"Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin\u20082006; 56: 226\u201343.","DOI":"10.3322\/canjclin.56.4.226"},{"key":"2022061700302244800_B7","doi-asserted-by":"crossref","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol\u20081998; 16: 2825\u201333.","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"2022061700302244800_B8","doi-asserted-by":"crossref","unstructured":"Maloney DG, Grillo-Lo\u0301pez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol\u20081997; 15: 3266\u201374.","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"2022061700302244800_B9","unstructured":"Eisenbeis CF, Caligiuri MA, Byrd JC. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res\u20082003; 9: 5810\u20132."},{"key":"2022061700302244800_B10","doi-asserted-by":"crossref","unstructured":"Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood\u20082001; 97: 1392\u20138.","DOI":"10.1182\/blood.V97.5.1392"},{"key":"2022061700302244800_B11","doi-asserted-by":"crossref","unstructured":"Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res\u20082005; 11: 5971\u201380.","DOI":"10.1158\/1078-0432.CCR-05-0554"},{"key":"2022061700302244800_B12","doi-asserted-by":"crossref","unstructured":"Iida S, Misaka H, Inoue M, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to Fc\u03b3RIIIa. Clin Cancer Res\u20082006; 12: 2879\u201387.","DOI":"10.1158\/1078-0432.CCR-05-2619"},{"key":"2022061700302244800_B13","doi-asserted-by":"crossref","unstructured":"Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood\u20082004; 104: 1793\u2013800.","DOI":"10.1182\/blood-2004-01-0039"},{"key":"2022061700302244800_B14","doi-asserted-by":"crossref","unstructured":"Nishida M, Usuda S, Okabe M, et al. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol\u20082007; 31: 29\u201340.","DOI":"10.3892\/ijo.31.1.29"},{"key":"2022061700302244800_B15","doi-asserted-by":"crossref","unstructured":"Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood\u20082003; 101: 1045\u201352.","DOI":"10.1182\/blood-2002-06-1761"},{"key":"2022061700302244800_B16","unstructured":"Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res\u20082003; 63: 5480\u201389."},{"key":"2022061700302244800_B17","unstructured":"Davis T, Kamiski M, Leonard J, Gregory S. Results of a randomized study of Bexxar (Tositumomab and I 131 Tositumomab) vs unlabeled Tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma [abstract]. Blood\u20082001; 98: 843a."},{"key":"2022061700302244800_B18","unstructured":"Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res\u20081992; 52: 6476\u201381."},{"key":"2022061700302244800_B19","doi-asserted-by":"crossref","unstructured":"Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood\u20081994; 83: 435\u201345.","DOI":"10.1182\/blood.V83.2.435.bloodjournal832435"},{"key":"2022061700302244800_B20","doi-asserted-by":"crossref","unstructured":"Meng R, Smallshaw JE, Pop LM, et al. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin Cancer Res\u20082004; 10: 1274\u201381.","DOI":"10.1158\/1078-0432.CCR-1154-03"},{"key":"2022061700302244800_B21","doi-asserted-by":"crossref","unstructured":"Liu XY, Pop LM, Roopenian DC, Ghetie V, Vitetta ES, Smallshaw JE. Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics. Int Immunopharmacol\u20082006; 6: 791\u20139.","DOI":"10.1016\/j.intimp.2005.11.022"},{"key":"2022061700302244800_B22","doi-asserted-by":"crossref","unstructured":"Li B, Wang H, Dai J, et al. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology\u20082005; 116: 487\u201398.","DOI":"10.1111\/j.1365-2567.2005.02247.x"},{"key":"2022061700302244800_B23","doi-asserted-by":"crossref","unstructured":"Looney RJ, Abraham GN, Anderson CL. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol\u20081986; 136: 1641\u20137.","DOI":"10.4049\/jimmunol.136.5.1641"},{"key":"2022061700302244800_B24","doi-asserted-by":"crossref","unstructured":"Jones DH, Looney RJ, Anderson CL. Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength. J Immunol\u20081985; 135: 3348\u201353.","DOI":"10.4049\/jimmunol.135.5.3348"},{"key":"2022061700302244800_B25","doi-asserted-by":"crossref","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods\u20081983; 65: 55\u201363.","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"2022061700302244800_B26","doi-asserted-by":"crossref","unstructured":"Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods\u20082002; 260: 285\u2013302.","DOI":"10.1016\/S0022-1759(01)00556-7"},{"key":"2022061700302244800_B27","unstructured":"Wolff EA, Schreiber GJ, Cosand WL, Raff HV. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res\u20081993; 53: 2560\u20135."},{"key":"2022061700302244800_B28","doi-asserted-by":"crossref","unstructured":"Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci U S A\u20081997; 94: 7509\u201314.","DOI":"10.1073\/pnas.94.14.7509"},{"key":"2022061700302244800_B29","doi-asserted-by":"crossref","unstructured":"Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis\u20082005; 64: 77\u201380.","DOI":"10.1136\/ard.2005.042507"},{"key":"2022061700302244800_B30","doi-asserted-by":"crossref","unstructured":"Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol\u20082003; 21: 1466\u201371.","DOI":"10.1200\/JCO.2003.06.012"},{"key":"2022061700302244800_B31","unstructured":"Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res\u20082003; 63: 36\u20138."},{"key":"2022061700302244800_B32","doi-asserted-by":"crossref","unstructured":"Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood\u20082004; 104: 1166\u201373.","DOI":"10.1182\/blood-2004-01-0277"},{"key":"2022061700302244800_B33","doi-asserted-by":"crossref","unstructured":"van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol\u20082001; 115: 807\u201311.","DOI":"10.1046\/j.1365-2141.2001.03166.x"},{"key":"2022061700302244800_B34","doi-asserted-by":"crossref","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood\u20081999; 94: 2217\u201324.","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224"},{"key":"2022061700302244800_B35","doi-asserted-by":"crossref","unstructured":"Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother\u20082001; 24: 263\u201371.","DOI":"10.1097\/00002371-200105000-00011"},{"key":"2022061700302244800_B36","unstructured":"Bannerji RPM, Flinn IW. Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy [abstract]. Blood\u20082000; 96: 164."},{"key":"2022061700302244800_B37","doi-asserted-by":"crossref","unstructured":"Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol\u20081998; 161: 3242\u20138.","DOI":"10.4049\/jimmunol.161.7.3242"},{"key":"2022061700302244800_B38","doi-asserted-by":"crossref","unstructured":"Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol\u20082006; 177: 362\u201371.","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"2022061700302244800_B39","doi-asserted-by":"crossref","unstructured":"Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes;heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood\u20082002; 99: 3256\u201362.","DOI":"10.1182\/blood.V99.9.3256"},{"key":"2022061700302244800_B40","doi-asserted-by":"crossref","unstructured":"Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood\u20082006; 107: 1070\u20137.","DOI":"10.1182\/blood-2005-04-1769"},{"key":"2022061700302244800_B41","doi-asserted-by":"crossref","unstructured":"Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood\u20082006; 108: 1975\u20138.","DOI":"10.1182\/blood-2006-04-014639"},{"key":"2022061700302244800_B42","doi-asserted-by":"crossref","unstructured":"Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem\u20082007; 282: 15073\u201380.","DOI":"10.1074\/jbc.M701654200"},{"key":"2022061700302244800_B43","doi-asserted-by":"crossref","unstructured":"Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther\u20082005; 7 Suppl 3: S19\u201325.","DOI":"10.1186\/ar1739"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/7\/2400\/2593407\/2400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/7\/2400\/2593407\/2400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T11:28:07Z","timestamp":1684322887000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/7\/2400\/540813\/Development-of-Novel-Tetravalent-Anti-CD20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2008,4,1]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-6663","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,1]]}}}